
    
      Comparison of the clinical pregnancy rate in the AFOLIA group compared to the US approved
      Gonal-f® RFF Redi-ject group as the primary endpoint. Comparison of the number and size of
      follicles, the number of cycle cancellation, the hormone parameters and adverse events in the
      AFOLIA group compared to the Gonal-f® RFF group as secondary endpoints.
    
  